Literature DB >> 10688088

Prostate cancer biochemical recurrence stage for stage is more frequent among African-American than white men with locally advanced but not organ-confined disease.

I J Powell1, M Banerjee, M Novallo, W Sakr, D Grignon, D P Wood, J E Pontes.   

Abstract

OBJECTIVES: To determine whether outcome differences between African-American men (AAM) and white men with prostate cancer (PCa) will still be present if we control for stage in a large cohort of men. It is well established that AAM have a worse outcome from PCa than white men.
METHODS: We examined 848 consecutive patients who underwent radical prostatectomy at Wayne State University, Karmanos Cancer Institute, between 1991 and 1995. The mean follow-up was 34 months (range 1.5 to 75). We included men with Gleason score 7 (4 + 3) with those men with Gleason score 8 to 10 for racial/ethnic comparisons.
RESULTS: AAM and white men diagnosed with organ-confined PCa demonstrated similar prostate-specific antigen (PSA) levels, Gleason grade, and biochemical recurrence. However, AAM diagnosed with non-organ-confined disease demonstrated higher PSA levels and a higher incidence of recurrence than did white men with non-organ-confined disease. There was a trend toward AAM having a greater proportion of high-grade lesions than white men when PCa was not organ confined. The evidence suggests that the difference in recurrence among AAM versus white men is based on pretreatment PSA, grade, extracapsular extension, and positive surgical margins. Seminal vesicle invasion predicted a worse prognosis equally for both AAM and white men.
CONCLUSIONS: A difference in biochemical recurrence was not detected between AAM and white men with organ-confined PCa after radical prostatectomy. PSA was higher in AAM than in white men with pathologically locally advanced PCa, and the biochemical recurrence was greater. AAM had a greater percentage of high Gleason grade lesions compared with white men, and this difference approached statistical significance. We hypothesize that AAM have a more rapid growth rate of PCa, which may be responsible for these clinical findings. Further investigations of the biology of PCa are needed to understand these findings.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10688088     DOI: 10.1016/s0090-4295(99)00436-7

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  19 in total

Review 1.  Measurement issues in health disparities research.

Authors:  Mildred Ramírez; Marvella E Ford; Anita L Stewart; Jeanne A Teresi
Journal:  Health Serv Res       Date:  2005-10       Impact factor: 3.402

2.  Factors influencing behavioral intention regarding prostate cancer screening among older African-American men.

Authors:  Marvella E Ford; Sally W Vernon; Suzanne L Havstad; Shirley A Thomas; Shawna D Davis
Journal:  J Natl Med Assoc       Date:  2006-04       Impact factor: 1.798

3.  Evaluating an intervention to increase cancer knowledge in racially diverse communities in South Carolina.

Authors:  Marvella E Ford; Amy E Wahlquist; Celina Ridgeway; June Streets; Katie A Mitchum; R Remus Harper; Ian Hamilton; J James W Etheredge; Melanie S Jefferson; Heidi Varner; Katora Campbell; Elizabeth Garrett-Mayer
Journal:  Patient Educ Couns       Date:  2010-07-31

4.  Epigenetic analysis identifies factors driving racial disparity in prostate cancer.

Authors:  Richa Rai; Shalini S Yadav; Heng Pan; Irtaza Khan; James O'Connor; Mohammed Alshalalfa; Elai Davicioni; Emanuela Taioli; Olivier Elemento; Ashutosh K Tewari; Kamlesh K Yadav
Journal:  Cancer Rep (Hoboken)       Date:  2018-12-13

Review 5.  Interactions among genes, tumor biology and the environment in cancer health disparities: examining the evidence on a national and global scale.

Authors:  Tiffany A Wallace; Damali N Martin; Stefan Ambs
Journal:  Carcinogenesis       Date:  2011-04-03       Impact factor: 4.944

6.  Racial influence on biochemical disease-free survival in men treated with external-beam radiotherapy for localized prostate cancer.

Authors:  Charles J Rosser; Deborah A Kuban; Sang-Joon Lee; Lawrence B Levy; Curtis Pettaway; Ashish M Kamat; Ramsey Chichakli; Andrew Lee; Rex M Cheung; Ricardo Sanchez-Ortiz; Louis L Pisters
Journal:  J Natl Med Assoc       Date:  2004-07       Impact factor: 1.798

7.  Evidence for molecular differences in prostate cancer between African American and Caucasian men.

Authors:  Francesca Khani; Juan Miguel Mosquera; Kyung Park; Mirjam Blattner; Catherine O'Reilly; Theresa Y MacDonald; Zhengming Chen; Abhishek Srivastava; Ashutosh K Tewari; Christopher E Barbieri; Mark A Rubin; Brian D Robinson
Journal:  Clin Cancer Res       Date:  2014-07-23       Impact factor: 12.531

Review 8.  Minireview: the molecular and genomic basis for prostate cancer health disparities.

Authors:  Isaac J Powell; Aliccia Bollig-Fischer
Journal:  Mol Endocrinol       Date:  2013-04-22

9.  Prostate cancer health disparities: An immuno-biological perspective.

Authors:  Sanjay Kumar; Rajesh Singh; Shalie Malik; Upender Manne; Manoj Mishra
Journal:  Cancer Lett       Date:  2017-11-15       Impact factor: 8.679

Review 10.  'Race' and prostate cancer mortality in equal-access healthcare systems.

Authors:  Tisheeka Graham-Steed; Edward Uchio; Carolyn K Wells; Mihaela Aslan; John Ko; John Concato
Journal:  Am J Med       Date:  2013-12       Impact factor: 4.965

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.